• 1
    Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003; 97(Suppl 12): 31333275.
  • 2
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Cancer. 2004; 100: 228237.
  • 3
    Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975; 135: 715719.
  • 4
    Chrischilles E, Link B, Scott S, Delgado DJ, Fridman M. Factors associated with early termination of CHOP, and its association with overall survival among patients with intermediate-grade non-Hodgkin's lymphoma (NHL) [abstract 1539]. Proc Am Soc Clin Oncol. 2002; 21: 385a.
  • 5
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730751.
  • 6
    Murono K, Hirano Y, Koyano S, Ito K, Fujieda K. Molecular comparison of bacterial isolates from blood with stains colonizing pharynx and intestine in immunocompromised patients with sepsis. J Med Microbiol. 2003; 52: 527530.
  • 7
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64: 328340.
  • 8
    Rolston KVI, Raad I, Whimbey E, Bodey GP. The changing spectrum of bacterial infections in febrile neutropenic patients. In: KlasterskyJA, editor. Febrile neutropenia. Berlin: Springer-Verlag, 1997: 5356.
  • 9
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36: 11031110.
  • 10
    Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003; 37: 11441145.
  • 11
    Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000; 160: 501509.
  • 12
    Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998; 16: 11791187.
  • 13
    Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia. Toward a more targeted antibiotic strategy. Clin Infect Dis. 2003; 36: 149158.
  • 14
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001; 33: 947953.
  • 15
    Fainstein V, Elting LS, Bodey GP. Bacteremia caused by non-sporulating anaerobes in cancer patients. A 12 year experience. Medicine (Baltimore). 1989; 68: 151162.
  • 16
    Sanders CC, Sanders WE Jr. Beta-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis. 1992; 15: 824839.
  • 17
    Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer. 2003; 97: 419424.
  • 18
    Minami S, Akama M, Arkai H, et al. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class-B beta-lactamase. J Antimicrob Chemother. 1996; 37: 433444.
  • 19
    Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002; 34: 15241529.
  • 20
    Kennedy HF, Gemmell CG, Bagg J, Gibson BE, Michie JR. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother. 2001; 47: 693696.
  • 21
    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992; 14: 12021207.
  • 22
    Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis. 1995; 20: 296301.
  • 23
    Zaas AK, Song X, Tucker P, Perl MT. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2000; 35: 11391146.
  • 24
    Montecalvo MA, Horowitz H, Gedric C, et al. Outbreak of vancomycin-ampicillin and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994; 38: 13631367.
  • 25
    Hachem RY, Rice L, Hanna H, et al. Molecular patterns of decreased vancomycin-resistant Enterococcus faecium (VREF) susceptibility to linezolid associated with clinical use [abstract 216]. 41st Annual Meeting of Infectious Diseases Society of America (IDSA). San Diego: Infectious Diseases Society of America, 2003.
  • 26
    Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003; 37: 180186.
  • 27
    Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2000; 21: 455458.
  • 28
    Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003; 362: 18281838.
  • 29
    Lessiones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis. 1992; 14: 875883.
  • 30
    Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in the United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29: 239244.
  • 31
    Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003; 82: 309321.
  • 32
    Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002; 23: 542545.
  • 33
    Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002; 359: 11351144.
  • 34
    Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002; 21: 161172.
  • 35
    Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003; 46: 2528.
  • 36
    Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis. 1996; 22(Suppl 2): S112S118.
  • 37
    Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998; 42: 497502.
  • 38
    Nucci M, Anaisse EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003; 98: 315319.
  • 39
    Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents. 2000; 16: 9395.
  • 40
    Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL. Randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci. 1984; 287: 1623.
  • 41
    Valdivieso M, Gil-Extremera B, Zornoza J, Rodriguez V, Bodey GP. Gram-negative bacillary pneumonia in the compromised host. Medicine. 1977; 56: 241254.
  • 42
    Raad I, Hanna HA, Alakech B, Chatzinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004; 140: 1825.
  • 43
    Allen U, Smith CR, Prober CG. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child. 1986; 140: 459461.
  • 44
    Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: use of high resolution computed tomography. J Clin Oncol. 1999; 17: 796805.
  • 45
    Klastersky J. Antifungal therapy in patients with fever and neutropenia-more rational and less empirical? N Engl J Med. 2004; 351: 14451447.
  • 46
    Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low risk subgroup at presentation. Arch Intern Med. 1988; 148: 25612568.
  • 47
    Elting LS, Rubenstein EB, Rolston KVI, et al. Outcome of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247259.
  • 48
    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992; 10: 316321.
  • 49
    Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18: 30383051.
  • 50
    McCube WR, Jackson GG. Gram-negative bacteremia II. Clinical, laboratory and therapeutic observations. Arch Intern Med. 1962; 110: 856864.
  • 51
    Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med. 1985; 145: 16211629.
  • 52
    Middleman E, Watanabe A, Kaizer H, Bodey GP. Antibiotic combinations for infections in neutropenic patients. Evaluation of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972; 30: 573579.
  • 53
    Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971; 284: 10611066.
  • 54
    Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients. A study of 494 consecutive patients. Cancer. 1978; 41: 16101622.
  • 55
    Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997; 24: 810815.
  • 56
    Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empiric therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 2002; 137: 7787.
  • 57
    Pizzo PA, Hathorn JW, Himenez J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986; 315: 552558.
  • 58
    Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1997; 41: 17041708.
  • 59
    Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996; 40: 11081115.
  • 60
    Raad II, Abi-Said D, Rolston KV, Karl CL, Bodey GP. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer. 1998; 82: 24492458.
  • 61
    Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin/tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001; 33: 12951301.
  • 62
    Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992; 152: 283291.
  • 63
    Feld R, DePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000; 18: 36903698.
  • 64
    Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer. 2003; 98: 10391047.
  • 65
    Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. 2000; 44: 32643271.
  • 66
    Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamycin sulfate therapy. Cancer. 1972; 29: 16971701.
  • 67
    Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003; 326: 11111119.
  • 68
    Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer. 2002; 10: 189196.
  • 69
    Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1995; 44(RR-12): 113.
  • 70
    European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991; 163: 951958.
  • 71
    Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999; 29: 503507.
  • 72
    Feld R, Bodey GP, Rodriguez V, Luna M. Causes of death in patients with malignant lymphoma. Am J Med Sci. 1974; 268: 97106.
  • 73
    Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003; 89: 4349.
  • 74
    Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993; 71: 36403646.
  • 75
    Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999; 341: 305311.
  • 76
    Kern WV, Cometta A, de Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999; 341: 312318.
  • 77
    Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004; 54: 2937.
  • 78
    Gardenmbas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol. 1991; 2: 485487.
  • 79
    Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol. 2000; 18: 36993706.
  • 80
    Pizzo PA, Robichard KJ, Gill FA. Duration of empiric antibiotic therapy in granulopenic patients with cancer. Am J Med. 1979; 67: 194199.
  • 81
    Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med. 2002; 346: 222224.
  • 82
    Mylotte JM, Tayara A. Blood cultures: clinical aspects and controversies. Eur J Clin Microbiol Infect Dis. 2000; 19: 157163.
  • 83
    Lazarus HM, Lowder JN, Anderson JM, Herzig RH. A prospective randomized trial of central venous catheter removal versus intravenous amphotericin B in febrile neutropenic patients. J Parenter Enteral Nutr. 1984; 8: 501505.
  • 84
    Press OV, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine. 1984; 63: 189200.
  • 85
    Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine. 1990; 69: 296306.
  • 86
    Bodey GP, Elting L, Jones P, Alvarez ME, Rolston K, Fainstein V. Imipenem/cilistatin therapy of infections in cancer patients. Cancer. 1987; 60: 255262.
  • 87
    Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72: 101111.
  • 88
    Talbot GH, Provencher M, Cassileth PA. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med. 1988; 148: 129135.
  • 89
    Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother. 2000; 45: 843849.
  • 90
    Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003; 37: 382389.
  • 91
    de Pauw BE, Deresinski SC, Feld R, Lane-Altman EF, Donnelly JP, for the Intercontinental Antimicrobial Study Group. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med. 1994; 120: 834844.
  • 92
    Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992; 11: 99109.
  • 93
    Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect. 2003; 53: 243258.
  • 94
    Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant. 1994; 14(Suppl 5): S15S17.